peripheral vascular disease
Cardiovascular · 2005–2005
2decisions
2medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ezetimibe Addition of two indications to the current listing for ezetimibe, namely peripheral vascular disease and heterozygous familial hypercholesterolaemia, on the… | Nov 2005 | Recommended with restriction | no section in document |
| ezetimibe; ezetimibe with simvastatin Addition of symptomatic peripheral vascular disease and heterozygous familial hypercholesterolaemia to the ezetimibe listing for co-administration with a… | Nov 2005 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.